Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet.

The U.S. FDA has approved Lupin's Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet as bioequivalent to the reference listed drug (RLD) Lokelma® for Oral Suspension of AstraZeneca Pharmaceuticals LP and is indicated for the treatment of hyperkalemia in adults.

Sodium Zirconium Cyclosilicate for Oral Suspension (RLD Lokelma®) had estimated annual sales of USD 568 million in the U.S. (IQVIA MAT Jun 2026).

Shares of Lupin Limited was last trading in BSE at Rs. 2275.00 as compared to the previous close of Rs. 2360.00. The total number of shares traded during the day was 196912 in over 7828 trades.

The stock hit an intraday high of Rs. 2366.20 and intraday low of 2236.00. The net turnover during the day was Rs. 447056238.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals Approval USA SodiumZirconiumCyclosilicate OralSuspension